Unlike other MARK members (MARK1-3), MARK4 is unique in its ability to exhibit direct association with microtubule (Trinczek et al., 2004), making MARK4 an attractive target to sensitize HCC to paclitaxel treatment. This evidence concerns the gene MARK1 and hepatocellular carcinoma.